ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 682,34
-0,54%
Dow Jones
40 211,72
0,53%
DAX
18 590,89
-0,95%
Brent Oil
84,095
-0,29%
Bitcoin
64 819,94
-0,05%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
24/05/202322h16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:TEVATeva Pharmaceutical Industries Ltd
20/05/202317h00Business WireTeva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
18/05/202314h30Business WireTeva Launches New “Pivot to Growth” StrategyNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/202314h00Business WireAUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
11/05/202322h01Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/202322h05Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/202313h00Business WireTeva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/202313h00Business WireTeva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of ScheduleNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202314h30Business WireU.S. Mental Health Access Program Expands Medicine Donation to Seven New StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/202302h22Business WireTeva et MedinCell annoncent l'approbation par la FDA américaine de UZEDY™ (risperidone), un antipsychotique sous forme de suspension injectable sous-cutanée à libération prolongée pour le traitement de la schizophrénie chez l'adulteNYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/202302h22Business WireTeva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in AdultsNYSE:TEVATeva Pharmaceutical Industries Ltd
27/04/202314h35Business WireTeva to Launch New Growth Strategy at Investor DayNYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/202322h18Edgar (US Regulatory)Annual Report to Security Holders (ars)NYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202322h15Business WireTeva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202320h28Dow Jones NewsTeva Shares Drop 11% After Alvotech Gets FDA Complete Response LetterNYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202302h53Business WireComplete Response Letter Received for AVT02 Biologics License ApplicationNYSE:TEVATeva Pharmaceutical Industries Ltd
11/04/202314h00Business WireTeva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
27/03/202314h00Business WireTeva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health SystemNYSE:TEVATeva Pharmaceutical Industries Ltd
13/03/202314h33Business WireTeva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/03/202314h00Business WireTeva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
08/03/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202322h00Business WireTeva to Present at the Barclays Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
03/03/202313h03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/03/202322h13Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/03/202322h11Business WireTeva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender OfferNYSE:TEVATeva Pharmaceutical Industries Ltd
27/02/202309h30Business WireTeva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
27/02/202309h30Business WireTeva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026NYSE:TEVATeva Pharmaceutical Industries Ltd
24/02/202314h00Business WireTeva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
23/02/202314h00Business WireTeva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ LivesNYSE:TEVATeva Pharmaceutical Industries Ltd
18/02/202300h03Dow Jones NewsTeva Gets FDA Approval for Movement Disorders TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
EU
ACA
Credit Agricole
EU
SGO
Cie de SaintGobain
EU
ML
Michelin
EU
VIV
Vivendi
EU
AF
Air FranceKLM
EU
BNP
BNP Paribas
EU
LR
Legrand
EU
GLE
Societe Generale
NASDAQ
MSFT
Microsoft
EU
RI
Pernod Ricard
EU
VK
Vallourec
USI
USTECH100
US Tech 100
EU
ORA
Orange
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés